This inadequacy can be overcome in some hemophilia A patients (e.g., those with antibodies to FVIII) using therapeutic augmentation of the extrinsic (TF-FVII) tenase pathway by intravenous FVII or subcutaneous concizumab, a monoclonal antibody against TFPI61. This evidence concerns the gene F8 and hemophilia A.